Edition:
United States

Veracyte Inc (VCYT.OQ)

VCYT.OQ on NASDAQ Stock Exchange Global Market

6.44USD
15 Dec 2017
Change (% chg)

$0.14 (+2.30%)
Prev Close
$6.30
Open
$6.28
Day's High
$6.56
Day's Low
$6.28
Volume
784,633
Avg. Vol
50,542
52-wk High
$9.78
52-wk Low
$5.75

Latest Key Developments (Source: Significant Developments)

Veracyte posts Q3 loss per share $0.21
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Veracyte Inc :Veracyte announces third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $17.5 million versus I/B/E/S view $19.5 million.Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $71 million to $72 million.Veracyte Inc - ‍narrowing range of its annual cash burn guidance to $25 to $26 million​.  Full Article

Veracyte reports Q2 loss per share $0.22
Monday, 31 Jul 2017 04:05pm EDT 

July 31 (Reuters) - Veracyte Inc -:Veracyte announces second quarter 2017 financial results.Q2 revenue $18.4 million versus I/B/E/S view $18.3 million.Sees FY 2017 revenue $76 million to $84 million.Qtrly loss per share $0.22.Veracyte Inc says reiterates its 2017 annual revenue guidance of $76 to $84 million and annual cash burn of $25 to $27 million.Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.FY2017 revenue view $77.0 million -- Thomson Reuters I/B/E/S.  Full Article

Veracyte says Anthem coverage for the Afirma gene expression classifier for use in thyroid cancer diagnosis
Thursday, 18 May 2017 12:18pm EDT 

May 18 (Reuters) - Veracyte Inc :Veracyte announces Anthem coverage for the Afirma® gene expression classifier for use in thyroid cancer diagnosis.Anthem Inc has issued positive coverage policy veracyte's Afirma Gene Expression Classifier (GEC) for use in thyroid cancer diagnosis.  Full Article

Veracyte announces Q1 revenue $16.4 million
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Veracyte Inc :Veracyte announces first quarter 2017 financial results.Q1 revenue $16.4 million versus I/B/E/S view $17.7 million.Sees FY 2017 revenue $76 million to $84 million.Veracyte Inc - Veracyte reiterates its 2017 annual revenue guidance of $76 to $84 million and annual cash burn of $25 to $27 million.Qtrly loss per share $0.24.Q1 revenue view $17.7 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.FY2017 revenue view $79.9 million -- Thomson Reuters I/B/E/S.  Full Article

Veracyte reports qtrly loss per share $0.14
Wednesday, 1 Mar 2017 04:05pm EST 

Veracyte Inc : Veracyte announces fourth quarter and full-year 2016 financial results, provides 2017 financial outlook . Veracyte Inc sees 2017 cash burn of $25 to $27 million, a reduction of 16 to 22 pct over prior year . Sees FY 2017 revenue $76 million to $84 million . Q4 revenue $18.3 million versus I/B/E/S view $17.5 million . Veracyte Inc - qtrly loss per share $0.14 . Q4 earnings per share view $-0.26, revenue view $17.5 million -- Thomson Reuters I/B/E/S .FY2017 earnings per share view $-0.93, revenue view $80.3 million -- Thomson Reuters I/B/E/S.  Full Article

Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis
Wednesday, 8 Feb 2017 08:00am EST 

Veracyte Inc : Veracyte to expand patient access to the Afirma gene expression classifier in thyroid cancer diagnosis through agreement with quest diagnostics . Says quest diagnostics is expected to begin offering test to its customers nationally in Q2 of 2017 . Says financial and other terms of agreement were not disclosed. .Physician clients of quest diagnostics will be able to order test on behalf of patients, refer patient specimens to co for genomic testing.  Full Article

Veracyte appoints Keith Kennedy as chief financial officer
Monday, 21 Nov 2016 08:00am EST 

Veracyte Inc : Veracyte - Keith Kennedy will succeed Shelly Guyer, who earlier this year announced her plan to step down as cfo .Veracyte Inc says Kennedy will join Veracyte effective December 6, 2016.  Full Article

Veracyte announces third quarter 2016 financial results
Thursday, 3 Nov 2016 04:05pm EDT 

Veracyte Inc : Veracyte announces third quarter 2016 financial results . Q3 loss per share $0.20 . Q3 revenue $18.6 million versus i/b/e/s view $16.7 million . Sees fy 2016 revenue $62 million to $65 million .Q3 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S.  Full Article

Veracyte announces launch of Envisia Genomic Classifier
Tuesday, 25 Oct 2016 08:00am EDT 

Veracyte Inc : Veracyte Inc says announces launch of envisia genomic classifier for improved diagnosis of idiopathic pulmonary fibrosis .Veracyte Inc says will begin making envisia genomic classifier available to a limited number of institutions in December.  Full Article

Veracyte sees 2016 revenue $59 million to $63 million
Wednesday, 3 Aug 2016 04:05pm EDT 

Veracyte Inc : Q2 loss per share $0.40 . Sees FY 2016 revenue $59 million to $63 million . Veracyte announces second quarter 2016 financial results . Q2 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S . Q2 revenue $14.7 million versus i/b/e/s view $14.8 million .Fy2016 earnings per share view $-1.29, revenue view $61.5 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Veracyte posts Q3 loss per share $0.21

* Q3 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S